We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4
Read MoreHide Full Article
Bayer AG (BAYRY - Free Report) reported fourth-quarter 2021 core earnings of 36 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 26 cents. The company reported earnings of 39 cents per ADR in the year-ago quarter.
Total sales in the fourth quarter were $12.66 billion, up from $11.92 billion in the year-ago quarter. Sales also beat the Zacks Consensus Estimate of $11.67 billion.
Shares of Bayer have plunged 8.5% in the past year against the industry’s rally of 19%.
Image Source: Zacks Investment Research
All growth rates mentioned below are on a year-over-year basis and after adjusting for currency and portfolio changes.
Full-Year Results
For 2021, Bayer reported core earnings of €6.51 per ADR compared with €6.39 per ADR reported in 2020.
The company generated revenues of €44.08 billion in 2021 compared with €41.40 billion in 2020. Revenues increased 8.9% (Fx & portfolio adj.).
Quarter in Detail
Bayer started reporting under three segments from the fourth quarter of 2019 — Pharmaceuticals, Consumer Health and Crop Science.
In the fourth quarter of 2021, Crop Science sales were €4.69 billion, up 8.8% from the year-ago quarter.
Revenues in the Pharmaceuticals segment rose 7.6% year over year to €4.95 billion in the reported quarter.
Consumer Health sales increased 8.6% year over year to €1.40 billion in the reported quarter.
2022 Guidance
Bayer expects to generate core earnings per share of €7 in 2022.
The company expects to generate sales of €46 billion in 2022.
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
Some better-ranked stocks in the healthcare sector are Cara Therapeutics, Inc. (CARA - Free Report) , Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) and Vertex Pharmaceuticals Incorporated (VRTX - Free Report) . While Cara Therapeutics currently sports a Zacks Rank #1 (Strong Buy), Catalyst Pharmaceuticals and Vertex both carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cara Therapeutics’ loss per share estimates has narrowed 1.3% for 2022 over the past 60 days.
CARA’s earnings surpassed estimates in three of the trailing four quarters and missed the same once.
Catalyst Pharmaceuticals’ earnings estimates have been revised 42% upward for 2022 over the past 60 days. The CPRX stock has skyrocketed 96.9% in the past year.
Catalyst Pharmaceuticals’ earnings have surpassed estimates in three of the trailing four quarters and met the same once.
Vertex’s earnings estimates have been revised 7.6% upward for 2022 over the past 60 days. The VRTX stock has gained 8.5% in the past year.
Vertex’s earnings have surpassed estimates in each of the trailing four quarters.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4
Bayer AG (BAYRY - Free Report) reported fourth-quarter 2021 core earnings of 36 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 26 cents. The company reported earnings of 39 cents per ADR in the year-ago quarter.
Total sales in the fourth quarter were $12.66 billion, up from $11.92 billion in the year-ago quarter. Sales also beat the Zacks Consensus Estimate of $11.67 billion.
Shares of Bayer have plunged 8.5% in the past year against the industry’s rally of 19%.
Image Source: Zacks Investment Research
All growth rates mentioned below are on a year-over-year basis and after adjusting for currency and portfolio changes.
Full-Year Results
For 2021, Bayer reported core earnings of €6.51 per ADR compared with €6.39 per ADR reported in 2020.
The company generated revenues of €44.08 billion in 2021 compared with €41.40 billion in 2020. Revenues increased 8.9% (Fx & portfolio adj.).
Quarter in Detail
Bayer started reporting under three segments from the fourth quarter of 2019 — Pharmaceuticals, Consumer Health and Crop Science.
In the fourth quarter of 2021, Crop Science sales were €4.69 billion, up 8.8% from the year-ago quarter.
Revenues in the Pharmaceuticals segment rose 7.6% year over year to €4.95 billion in the reported quarter.
Consumer Health sales increased 8.6% year over year to €1.40 billion in the reported quarter.
2022 Guidance
Bayer expects to generate core earnings per share of €7 in 2022.
The company expects to generate sales of €46 billion in 2022.
Bayer Aktiengesellschaft Price, Consensus and EPS Surprise
Bayer Aktiengesellschaft price-consensus-eps-surprise-chart | Bayer Aktiengesellschaft Quote
Zacks Rank & Stocks to Consider
Bayer currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Cara Therapeutics, Inc. (CARA - Free Report) , Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) and Vertex Pharmaceuticals Incorporated (VRTX - Free Report) . While Cara Therapeutics currently sports a Zacks Rank #1 (Strong Buy), Catalyst Pharmaceuticals and Vertex both carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cara Therapeutics’ loss per share estimates has narrowed 1.3% for 2022 over the past 60 days.
CARA’s earnings surpassed estimates in three of the trailing four quarters and missed the same once.
Catalyst Pharmaceuticals’ earnings estimates have been revised 42% upward for 2022 over the past 60 days. The CPRX stock has skyrocketed 96.9% in the past year.
Catalyst Pharmaceuticals’ earnings have surpassed estimates in three of the trailing four quarters and met the same once.
Vertex’s earnings estimates have been revised 7.6% upward for 2022 over the past 60 days. The VRTX stock has gained 8.5% in the past year.
Vertex’s earnings have surpassed estimates in each of the trailing four quarters.